Top Page | English | 简体中文 | 繁體中文 | 한국어 | 日本語
Thursday, 6 April 2023, 17:32 HKT/SGT
Share:
    

Source: Eisai
Eisai Completes a Major Renovation of Tsukuba Research Laboratories
As a Global Drug Discovery Center Aiming for Connecting Human and Human, and Data, and The World

TOKYO, Apr 6, 2023 - (JCN Newswire) - Eisai Co., Ltd. today announced the completion of a major renovation of its Tsukuba Research Laboratories (Ibaraki, Japan), which is a part of strategic investment to execute Eisai's medium-term business plan "EWAY Future & Beyond".

Eisai implements research and development activities under the DHBL (Deep Human Biology Learning) drug discovery and development system in our efforts to create new drugs based on innovative and efficient next-generation drug discovery concepts. For this purpose, we recognize diseases as Disease Continuum to redefine their concepts through comprehensive analysis on genomic, pathophysiological and clinical information associated with underlying causes of disease in order to enhance our understanding on human biology by acquiring data leading to next drug discovery with information, such as biomarkers and imaging data from patients on our drugs. Tsukuba Research Laboratories is positioned as a core facility in the DHBL drug discovery and development system. This renovation seeks to accelerate knowledge circulation by connecting each researcher with patients, other members within the Laboratories, other research sites across the world, and external researchers based on our key concept "Human Connected Laboratories: Laboratories Connecting Human and Human, and Data, and the World." Total investment on this major renovation was 8.5 billion yen.

Main Idea of This Major Renovation

[Designs to Enhancing Connection with Patients]
In the Eisai Group, all employees around the world use 1% of their total business hours to interact with patients (socialization) to understand their thoughts and feelings. Accordingly, we have been working on the initiatives (hhc activities) to lead value creation for patients. To enhance the opportunities for closer interaction with people outside the company, such as further socialization with patients, at Tsukuba Research Laboratories, a traffic line from the front gate through the main building lobby to the courtyard is placed as interactive zone to enable various communications.

[Realizing Connections between Researchers and Data Driven Drug Discovery]
In favor of generating natural communication between researchers across different therapeutic areas on a daily basis, workspaces for biology researchers and data scientists are allocated on the same floor, and likewise workspaces for chemistry and pharmacokinetics/analytical researchers are placed on nearby floors to foster new connections and knowledge exchange. Further creative solutions are implemented in laboratories, including collective arrangement of structural openings and devices. These designs facilitate data driven drug discovery through knowledge exchange.

[Knowledge Circulation Generated from Links between Buildings]
Corridors linking multiple buildings embodying the concept of Knowledge Circulation are placed. A traffic line named "Knowledge Corridor" enables people to move all around the laboratory, with which research efficiency and convenience are considerably improved.

[Meeting Rooms Value Connection with the World]
Each meeting room is equipped with an IT environment that allows smooth communication with overseas offices, as well as systems able to deal with hybrid meeting which dominantly accepted in recent days.

Eisai will accelerate the drug discovery activities under the DHBL drug discovery system in order to fulfill unmet medical needs, and in our efforts to further contribute to improve the benefits of patients and the people in the daily living domain.

Media Inquiries:
Public Relations Department,
Eisai Co., Ltd.
+81-(0)3-3817-5120

For more information, visit www.eisai.com/news/2023/news202328.html.


Topic: Press release summary
Source: Eisai

Sectors: BioTech
http://www.acnnewswire.com
From the Asia Corporate News Network


Copyright © 2024 ACN Newswire. All rights reserved. A division of Asia Corporate News Network.



Eisai
Nov 20, 2024 10:51 HKT/SGT
Rozebalamin for Injection 25mg (Mecobalamin) for Amyotrophic Lateral Sclerosis Launched in Japan
Nov 20, 2024 09:24 HKT/SGT
Anticancer Agent "TASFYGO Tablets 35mg" (Tasurgratinib Succinate) Launches in Japan for Biliary Tract Cancer with FGFR2 Gene Fusion or Rearrangements
Nov 15, 2024 16:33 HKT/SGT
Nationwide TV Commercial Launched in Japan to Raise Awareness About MCI (Mild Cognitive Impairment)
Nov 15, 2024 13:31 HKT/SGT
Eisai Receives Positive Opinion from the CHMP in the European Union for Lecanemab in Early Alzheimer's Disease
Nov 5, 2024 10:35 HKT/SGT
Eisai's Corporate Venture Capital Subsidiary, Eisai Innovation, Inc., Selected for AMED's 'Strengthening Program for Pharmaceutical Startup Ecosystem"
Nov 1, 2024 12:56 HKT/SGT
Eisai Completes Rolling Submission to US FDA for LEQEMBI(R) (lecanemab-irmb) Biologics License Application for Subcutaneous Maintenance Dosing for the Treatment of Early Alzheimer's Disease Under the Fast Track Status
Oct 31, 2024 12:56 HKT/SGT
Eisai Presents Data on Benefits of Long-Term Administration of Dual-Acting Lecanemab at the 17th Clinical Trials for Alzheimer's Disease (CTAD) Conference
Oct 31, 2024 10:33 HKT/SGT
Eisai Presents Latest Clinical Findings Suggesting Inhibition of Tau Propagation by Anti-MTBR Tau Antibody E2814 at the 17th Clinical Trials on Alzheimer's Disease Conference (CTAD)
Oct 17, 2024 19:01 HKT/SGT
A Joint Regional Cohort Study by Shimadzu, Eisai, Oita University, and Usuki City Medical Association
Oct 17, 2024 14:59 HKT/SGT
Update on Regulatory Review of Lecanemab for Early Alzheimer's Disease in Australia
More news >>
 News Alerts
Copyright © 2024 ACN Newswire - Asia Corporate News Network
Home | About us | Services | Partners | Events | Login | Contact us | Privacy Policy | Terms of Use | RSS
US: +1 214 890 4418 | China: +86 181 2376 3721 | Hong Kong: +852 8192 4922 | Singapore: +65 6549 7068 | Tokyo: +81 3 6859 8575

Connect With us: